Member Contact: Michael Johnson
Position: CEO and Managing Director
Industry: Medtech & Digital
Rhinomed (ASX:RNO: OTCQB:RHMF) is a Melbourne, Australia based, globally focused nasal and respiratory technology company. Through our proprietary platform technology (protected by a family of over 60 patents and 57 design patents, brands and trademarks) that focuses on the role and function of the nose we seek to radically improve the way people breathe, sleep, take medication and maintain their health and wellness. Our relentless focus on understanding and identifying consumer, clinician and patient needs drives the design and development of leading edge consumer health products, clinical devices and solutions that are now sold on over 20,000 pharmacy shelves globally including leading pharmacy chains, Walgreens, CVS and Rite Aid in the US and Boots in the UK, as well as through the Symbion and Sigma networks here in Australia.
Rhinomed continues to develop and assess opportunities for our nasal platform in the global sleep, breathing, nasal drug delivery and diagnostic markets. Our belief is that Australian based, but globally focused companies can not only innovate, but also successfully commercialise Australian developed technology on the world stage.